Trastuzumab
|
Better Known as: Herceptin
- Marketed By: Genentech
- Major Indication: Breast Cancer
- Drug Class: Human Epidermal Growth Factor Receptor 2 (HER2) Inhibitor
- Date of FDA Approval (Discontinued): 1998 (2015)
- 2008 Sales: $4.75 Billion
- Importance: It is a very effective treatment against HER2-positive metastatic breast cancer compared to other cancer therapies. Controversial due to its cost of nearly $100,000 per year. Is often pointed to as an example of the benefits of personalized medicine in which a patent's genetic profile is used to optimize their medication regimen.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
Mechanism of Action
Pharmacokinetics
| EGFR Inhibitor Pharmacokinetics[1] | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Trastuzumab | ||||||||||
| Tmax (hr) | 1.7 | ||||||||||
| Cmax (ng/ml) | 203000 | ||||||||||
| Bioavailability (%) | |||||||||||
| T1/2 (days) | 27 | ||||||||||
| AUC (ug/ml/hr) | 45036 | ||||||||||
| Clearance (L/h) | .009 | ||||||||||
| Dosage (mg) | 250 | ||||||||||
| Metabolism | Unknown | ||||||||||
References
- ↑ Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003 Nov 1;21(21):3965-71. Epub 2003 Sep 24. PMID:14507946 doi:10.1200/JCO.2003.12.109